Compare CAAS & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAAS | RANI |
|---|---|---|
| Founded | N/A | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 130.6M | 132.7M |
| IPO Year | N/A | 2021 |
| Metric | CAAS | RANI |
|---|---|---|
| Price | $4.56 | $1.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 26.0K | ★ 1.2M |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.68 | N/A |
| EPS | ★ 1.11 | N/A |
| Revenue | ★ $725,260,000.00 | $1,200,000.00 |
| Revenue This Year | N/A | $414.59 |
| Revenue Next Year | N/A | $30.15 |
| P/E Ratio | $4.13 | ★ N/A |
| Revenue Growth | ★ 16.72 | N/A |
| 52 Week Low | $3.50 | $0.39 |
| 52 Week High | $5.37 | $3.87 |
| Indicator | CAAS | RANI |
|---|---|---|
| Relative Strength Index (RSI) | 50.81 | 42.92 |
| Support Level | $4.51 | $1.34 |
| Resistance Level | $4.79 | $1.44 |
| Average True Range (ATR) | 0.19 | 0.07 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 20.69 | 21.74 |
China Automotive Systems Inc is a holding company. The firm through its subsidiary is a supplier of power steering systems and components to China's automotive industry. Its product offering encompasses a full range of auto parts incorporated into steering systems for both passenger automobiles and commercial vehicles. The company offers four separate series, models of power steering including rack and pinion power steering, integral power steering, electronic power steering and manual steering, steering columns, steering oil pumps, and steering hoses. Geographically, it derives a majority of its revenue from China.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.